ScholarLens Back to search
2010•China Modern MedicineRequires access

Observation of spironolactone in treating chronic heart failure

Xiao Xuan Lei

Open publisher page 0 citations

Abstract

Objective:To compare the effectiveness and safety of spironolactone in treating chronic heart failure in addition to benazepril and betaloc therapy.Methods:84 patients with chronic heart failure were randomly divided into two groups,spironolactone group(42 cases) and control group(42 cases).After 6 months' therapy,blood pressure,blood biochem istry,left ventricular end-diastolic volume(LVEDV),left ventricular end-systolic volume(LVESV),left ventricular ejection fraction(LVEF) and VE/VA were measued.The incidence of high kalium was recorded.Results:LVEDV,LVESV,LVEF and VE/VA of the patients in the spironolactone group were significantly improved(P0.05),which were significantly different from that of the control group(P0.05).The heart function of the patients was found much improved compared with controls.Conclusion:Adding spironolactone to benazepril and betaloc therapy is effective and safe in improving left ventricular function of patients with chronic heart failure.

About this research paper

What this paper is about

Objective:To compare the effectiveness and safety of spironolactone in treating chronic heart failure in addition to benazepril and betaloc therapy.Methods:84 patients with chronic heart failure were randomly divided into two groups,spironolactone group(42 cases) and control group(42 cases).After 6 months' therapy,blood pressure,blood biochem istry,left ventricular end-diastolic volume(LVEDV),left ventricular end-systolic volume(LVESV),left ventricular ejection fraction(LVEF) and VE/VA were measued.The incidence of high kalium was recorded.Results:LVEDV,LVESV,LVEF and VE/VA of the patients in the spironolactone group were significantly improved(P0.05),which were significantly different from that of the control group(P0.05).The heart function of the patients was found much improved compared with controls.Conclusion:Adding spironolactone to benazepril and betaloc therapy is effective and safe in improving left ventricular function of patients with chronic heart failure.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To compare the effectiveness and safety of spironolactone in treating chronic heart failure in addition to benazepril and betaloc therapy.Methods:84 patients with chronic heart failure were randomly divided into two groups,spironolactone group(42 cases) and control group(42 cases).After 6 months' therapy,blood pressure,blood biochem istry,left ventricular end-diastolic volume(LVEDV),left ventricular end-systolic volume(LVESV),left ventricular ejection fraction(LVEF) and VE/VA were measued.The incidence of high kalium was recorded.Results:LVEDV,LVESV,LVEF and VE/VA of the patients in the spironolactone group were significantly improved(P0.05),which were significantly different from that of the control group(P0.05).The heart function of the patients was found much improved compared with controls.Conclusion:Adding spironolactone to benazepril and betaloc therapy is effective and safe in improving left ventricular function of patients with chronic heart failure.

Key concepts: Spironolactone, Medicine, Benazepril, Ejection fraction, Heart failure, Internal medicine, Cardiology, Blood pressure

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Observation of spironolactone in treating chronic heart failure — Research Paper | ScholarLens